Novartis AG (NVSEF)
OTCMKTS · Delayed Price · Currency is USD
123.76
+1.18 (0.97%)
Sep 16, 2025, 1:44 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $14.84B in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
55.19B
Revenue Growth
+12.95%
P/S Ratio
4.31
Revenue / Employee
727.25K
Employees
75,883
Market Cap
238.00B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Novartis AG News
- 4 days ago - Novartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued. - Barrons
- 4 days ago - Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concerns - GuruFocus
- 4 days ago - Novartis cut to Sell at Goldman Sachs on near-term risks - Seeking Alpha
- 4 days ago - This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
- 4 days ago - Novartis (NVS) Downgraded to Sell by Goldman Sachs | NVS Stock News - GuruFocus
- 6 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 7 days ago - Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action - Seeking Alpha
- 7 days ago - Novartis Buys Tourmaline Bio in $1.4 Billion Heart Drug Deal(edit) - GuruFocus